GSK’s MUSCA study shows Nucala (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype

21st March 2017 Uncategorised 0

GlaxoSmithKline

More: GSK’s MUSCA study shows Nucala (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype
Source: MDlinx